Kimberly-Clark said fourth-quarter net sales of $5.0 billion were in line with the prior year, with organic sales up 3%. The company said a 2% price increase and a 1% mix improvement contributed, and volumes were in line with the prior year period.

1. 01

   Kimberly-Clark said fourth-quarter net sales of $5.0 billion were in line with the prior year, with organic sales up 3%. The company said a 2% price increase and a 1% mix improvement contributed, and volumes were in line with the prior year period.

2. 02

   Kimberly-Clark said full-year 2023 operating profit fell to $2.34 billion from $2.68 billion in 2022, and that this result included a non-cash impairment charge on intangible assets. The company said adjusted operating profit for 2022 rose to $2.96 billion from $2.62 billion.

3. 03

   Kimberly-Clark said full-year 2023 cash provided by operations was $3.5 billion, up from $2.7 billion a year earlier. It said it returned $1.8 billion to shareholders through dividends and share repurchases, and that it repurchased 1.8 million shares for $225 million.

4. 04

   The company said it expects organic net sales for 2024 to grow at a low-to-mid single-digit rate versus the prior year. It said reported net sales growth is expected to reflect negative impacts of about 300 basis points from currency translation and about 60 basis points from the Brazil Tissue divestiture.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.